Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
By the Numbers (Clinical Trial Averages): Tirzepatide Wins for: Greater Average Weight Loss: 22.5% vs 14.9% More Patients Reaching 20% Loss: 63% vs not reported Higher Percentage Reaching 15% Loss: 78% vs 50.5% Continued Weight Loss: Patients continued losing weight throughout 72 weeks Semaglutide Still Highly Effective: 86% of patients lost at least 5% of body weight 69% of patients lost at least 10% of body weight Longer market history with real-world data Proven cardiovascular benefits in studies Factors Beyond Weight Loss Numbers: Side Effect Tolerance: If you experience severe nausea with one medication, the one you can actually take consistently is the more effective choice for you
M., Power, J., Diamond, M., Polzien, K., & Foster, G
Morello, Pharm D, CDE, FCSHP, FASHP, Associate Dean for Student Affairs at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, Clinical Pharmacist Specialist at VASDHS.
Following a regular review of unblinded data, an independent monitoring board concluded that ziritaxestats benefit-risk profile no longer supported continuing these studies. Gilead said the phase 3 program is to be canned
